Hunan Er-Kang Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Qingrong Sun

İcra Kurulu Başkanı

CN¥335.7k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

Qingrong Sun (38 yo)

5yrs

Görev süresi

CN¥335,700

Tazminat

Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qingrong Sun	GM & Non-Independent Director	5yrs	CN¥335.70k	Veri yok
Zhao Xun	CFO & Non Independent Director	no data	CN¥389.10k	Veri yok
Xiangyang Shi	Deputy GM & Non Independent Director	no data	CN¥535.10k	Veri yok
Jishun Gu	Deputy GM & Board Secretary	4.7yrs	CN¥514.20k	0.0017% CN¥ 108.0k
Licheng Zhang	Deputy General Manager	no data	CN¥422.70k	Veri yok
Wang Hui	Deputy General Manager	5yrs	CN¥365.30k	Veri yok

5.0yrs

Ortalama Görev Süresi

42.5yo

Ortalama Yaş

Deneyimli Yönetim: 300267 'un yönetim ekibi deneyimli ve deneyimlidir ( 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qingrong Sun	GM & Non-Independent Director	2yrs	CN¥335.70k	Veri yok
Zhao Xun	CFO & Non Independent Director	5yrs	CN¥389.10k	Veri yok
Xiangyang Shi	Deputy GM & Non Independent Director	6.2yrs	CN¥535.10k	Veri yok
Fangwen Shuai	Chairman of the Board	no data	CN¥512.60k	41.38% CN¥ 2.6b
Junwen Wang	Independent Director	5yrs	CN¥150.00k	Veri yok
Wuzhen Jiang	Independent Director	5yrs	CN¥150.00k	Veri yok
Qing Peng	Chairman of Supervisory Board	3.5yrs	Veri yok	Veri yok
Xue Tan	Independent Director	2yrs	CN¥150.00k	Veri yok
Haiyi Li	Non-Employee Supervisor	2yrs	Veri yok	Veri yok
Hong Wang	Supervisor	2yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300267 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Hunan Er-Kang Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: CN¥0.015 loss per share (vs CN¥0.006 loss in 3Q 2023)

New major risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.013 in 2Q 2023)

New minor risk - Share price stability

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.095 loss per share (vs CN¥0.022 profit in FY 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Hunan Er-Kang Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.004 in 2Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2022 Final Profit Distribution, Payable on 09 June 2023

Hunan Er-Kang Pharmaceutical Co., Ltd Approves 2022 Profit Distribution Plan

First quarter 2023 earnings released: EPS: CN¥0.013 (vs CN¥0.011 in 1Q 2022)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.026 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.024 in 2Q 2021)

Full year 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.098 profit in FY 2020)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.056 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.024 (vs CN¥0.021 in 2Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 09, June 2021

Hunan Er-Kang Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.012 in 1Q 2020)

Hunan Er-Kang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥3.79

New 90-day low: CN¥4.17

New 90-day low: CN¥4.62

Third quarter earnings released

Huang Shubiao, Xiao Qingguang, Wu Kaijian, and Huang Linggang completed the acquisition of 95% stake in Guangdong Yueerkang Pharmaceutical Co., Ltd. from Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267).

New 90-day high - CN¥5.23

First half earnings released

Hunan Er-Kang Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş